Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | S100A9 | P06702 | 6/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16235465 | 0.79 | ALDH1A1 (0.44) | ALDH1A1NPSR1LMNAPOLBMAPT | |
| SCHEMBL3633110 | 0.73 | ALDH1A1 (0.43) | ALDH1A1NPSR1LMNAPOLBMAPT | |
| SCHEMBL16235474 | 0.73 | S100A9 (0.40) | ALDH1A1NPSR1LMNAPOLBMAPT | |
| SCHEMBL2420112 | 0.73 | SLC6A4 (0.40) | ALDH1A1NPSR1MAPTKDM4E | |
| SCHEMBL16235499 | 0.71 | S100A9 (0.39) | ALDH1A1LMNAPOLBKDM4ES100A9 | |
| SCHEMBL24425804 | 0.71 | ALDH1A1 (0.42) | ALDH1A1NPSR1MAPTS100A9 | |
| SCHEMBL2746172 | 0.71 | ALDH1A1 (0.38) | ALDH1A1NPSR1LMNAPOLBMAPT | |
| SCHEMBL7665056 | 0.71 | KDM4E (0.54) | ALDH1A1KDM4E | |
| SCHEMBL8272903 | 0.70 | ALDH1A1 (0.44) | ALDH1A1NPSR1LMNAPOLBMAPT | |
| SCHEMBL3710485 | 0.70 | ALDH1A1 (0.43) | ALDH1A1NPSR1LMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV2 | ALDH1A1 1188/4885NPSR1 122/4885LMNA 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.